Smoking status and vascular risk factors as predictors of disability in AQP4-NMOSD and MOGAD
Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: Smoking and vascular risk factors (VRFs) are reported to have adverse effects in multiple sclerosis but data are limited in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD). This study aimed to measure their impact on disability. Methods: Smoking status was defined as never, past or current smokers and VRF comprised of ⩾1: hypertension, dyslipidemia, high body mass index or diabetes. Logistic regression models were fitted to predict their influence on recovery from onset attack and first optic neuritis (ON) attack. Results: A total of 442 patients were included. Current MOGAD smokers had a higher risk of disability from onset attack and first ON attack than never smokers (odds ratio (OR) 2.9, 95% confidence interval (CI) 1.3–6.9; OR 3.3, 95% CI 1.4–7.8). VRF in MOGAD was not predictive of disability. Current AQP4-NMOSD smokers and VRFs had a higher risk of residual disability from onset attacks (OR 7.5, 95% CI 2.1–27.7; OR 1.9, 95% CI 1.0–3.4). VRF was associated with higher risk of visual disability (OR 2.6, 95% CI 1.08–6.46) while smoking status was not. Conclusions: Current smoking status detrimentally influenced onset attack recovery in AQP4-NMOSD and MOGAD patients, including visual recovery in MOGAD. Non-smoking VRFs influenced clinical and visual outcomes in AQP4-NMOSD.
Source: Multiple Sclerosis Journal
Institutions: The University of Sydney, University of Oxford, University of Lisbon, Unidade Local de Saúde de São José, Hospital de São José, University of Southern Denmark, Humboldt-Universität zu Berlin, Slagelse Hospital, Charité - Universitätsmedizin Berlin, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Frimley Health NHS Foundation Trust
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,400
Funders: Amgen, Sanofi, Biogen, Alexion Pharmaceuticals, Guthy-Jackson Charitable Foundation, European Committee for Treatment and Research in Multiple Sclerosis, Argenx, Horizon Therapeutics, University of Oxford, Fondation Charcot, Santa Casa da Misericórdia de Lisboa, Chugai Pharmaceutical, UCB Pharma
OpenAlex ID: W4408480951
